TSC Ratings' Updates: Limited Brands
KBR had been rated a hold since March 24, 2008.
Acorda Therapeutics (ACOR) has been downgraded from hold to sell. Acorda Therapeutics identifies, develops and commercializes novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. The company's drug, Zanaflex Capsules, is FDA-approved for the management of spasticity. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.
The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared with that of the S&P 500 and the biotechnology industry. The net income has significantly decreased by 130.6% when compared with the same quarter one year ago, falling from -$8.16 million to -$18.82 million.
Current return on equity is lower than its return on equity from the same quarter one year prior. This is a clear sign of weakness within the company. Compared with other companies in the biotechnology industry and the overall market, ACOR's return on equity significantly trails that of both the industry average and the S&P 500.
Net operating cash flow has significantly decreased to -$8.42 million or 114.38% when compared with the same quarter last year. In addition, when comparing it with the industry average, the firm's growth rate is much lower. ACOR has experienced a steep decline in earnings per share in the most-recent quarter in comparison with its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, ACOR has continued to lose money by earning -$1.43 vs. -$3.10 in the prior year. For the next year, the market is expecting a contraction of 47.5% in earnings (-$2.11 vs. -$1.43).Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
